Turn Therapeutics Inc. (TTRX) earnings date
Mar 30, 2027, after close estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 35% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-18
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 43 days, typically, give or take 22 (last 5 releases) |
Last 5 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Mon, Nov 9, 2026 | before open | 40 | 8-K |
| Q2 FY2026 | Wed, Aug 12, 2026 | after close | 43 | 8-K |
| Q1 FY2026 | Mon, May 11, 2026 | after close | 41 | 8-K |
| Q4 FY2025 | Tue, Mar 31, 2026 | after close | 90 | 8-K |
| Q3 FY2025 | Thu, Nov 13, 2025 | before open | 44 | 8-K |
What they guided beta
| Q3 FY2026 | "Building on GX-03 Momentum, Turn Therapeutics Accelerates Hidradenitis Suppurativa Trial with Enrollment Now Expected to Begin in First Quarter 2027" exhibit |
| Q3 FY2026 | "Company Expects Cash to Fund Operations into Third Quarter of 2027, with Additional Tranches of Capital Available from Existing Facilities" exhibit |
| Q3 FY2026 | "Turn Therapeutics expects to report topline results from the Phase 2b trial in the first quarter of 2027." exhibit |
| Q3 FY2026 | "We are also accelerating patient enrollment in the planned Phase 2a trial of GX-03 for hidradenitis suppurativa (HS) which is now expected to begin in the first quarter of 2027, ahead of the previously announced second-quarter target." exhibit |
| Q3 FY2026 | "With HS enrollment beginning and our Phase 2b atopic dermatitis trial moving forward, we expect the first quarter of 2027 to be a very active time for Turn." exhibit |
| Q2 FY2026 | "Phase 2 Enrollment Expected to Complete in Fourth Quarter of 2026; Company Expects Cash to Fund Operations into Third Quarter of 2027" exhibit |
| Q2 FY2026 | "The study continued without interruption during the interim review, and the Company remains on track to complete enrollment by the end of 2026." exhibit |
| Q2 FY2026 | "The Company is targeting first patient enrollment in the second quarter of 2027." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/TTRX
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/TTRX
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/TTRX/"><img src="https://veritasdata.dev/embed/TTRX.svg" alt="TTRX earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/TTRX/)
Script
<script async src="https://veritasdata.dev/embed/TTRX.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/TTRX"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.